CL2023001266A1 - Composition comprising a combination of immune checkpoint inhibitor - Google Patents
Composition comprising a combination of immune checkpoint inhibitorInfo
- Publication number
- CL2023001266A1 CL2023001266A1 CL2023001266A CL2023001266A CL2023001266A1 CL 2023001266 A1 CL2023001266 A1 CL 2023001266A1 CL 2023001266 A CL2023001266 A CL 2023001266A CL 2023001266 A CL2023001266 A CL 2023001266A CL 2023001266 A1 CL2023001266 A1 CL 2023001266A1
- Authority
- CL
- Chile
- Prior art keywords
- composition
- immune checkpoint
- checkpoint inhibitor
- combination
- amatoxin
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 title abstract 2
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 title abstract 2
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 title abstract 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 title abstract 2
- WVHGJJRMKGDTEC-WCIJHFMNSA-N 2-[(1R,4S,8R,10S,13S,16S,27R,34S)-34-[(2S)-butan-2-yl]-8,22-dihydroxy-13-[(2R,3S)-3-hydroxybutan-2-yl]-2,5,11,14,27,30,33,36,39-nonaoxo-27lambda4-thia-3,6,12,15,25,29,32,35,38-nonazapentacyclo[14.12.11.06,10.018,26.019,24]nonatriaconta-18(26),19(24),20,22-tetraen-4-yl]acetamide Chemical compound CC[C@H](C)[C@@H]1NC(=O)CNC(=O)[C@@H]2Cc3c([nH]c4cc(O)ccc34)[S@](=O)C[C@H](NC(=O)CNC1=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H]([C@@H](C)[C@H](C)O)C(=O)N2 WVHGJJRMKGDTEC-WCIJHFMNSA-N 0.000 abstract 2
- 231100000729 Amatoxin Toxicity 0.000 abstract 2
- 108010014709 amatoxin Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6831—Fungal toxins, e.g. alpha sarcine, mitogillin, zinniol or restrictocin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente solicitud se refiere a una composición que comprende (a) al menos un inhibidor de punto de control inmunitario y (b) al menos un conjugado, en donde dicho conjugado comprende (i) un resto de unión a diana, (ii) al menos una amatoxina y, (iii) opcionalmente, al menos un enlazador que conecta dicho resto de unión a diana con dicha al menos una amatoxina. La presente solicitud se refiere además a dicha composición para uso en el tratamiento de un paciente con cáncer, y a una formulación farmacéutica que comprende dicha composición y excipientes adicionales, así como métodos de producción y uso de dicha composición.The present application relates to a composition comprising (a) at least one immune checkpoint inhibitor and (b) at least one conjugate, wherein said conjugate comprises (i) a target binding moiety, (ii) at at least one amatoxin and, (iii) optionally, at least one linker connecting said target binding moiety to said at least one amatoxin. The present application further relates to said composition for use in the treatment of a patient with cancer, and to a pharmaceutical formulation comprising said composition and additional excipients, as well as methods of production and use of said composition.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20205794 | 2020-11-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023001266A1 true CL2023001266A1 (en) | 2023-12-15 |
Family
ID=73288362
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023001266A CL2023001266A1 (en) | 2020-11-04 | 2023-05-02 | Composition comprising a combination of immune checkpoint inhibitor |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP4240424A1 (en) |
| JP (1) | JP2023548522A (en) |
| KR (1) | KR20230104653A (en) |
| CN (1) | CN116744969A (en) |
| AU (1) | AU2021373298A1 (en) |
| CA (1) | CA3195572A1 (en) |
| CL (1) | CL2023001266A1 (en) |
| IL (1) | IL302034A (en) |
| MX (1) | MX2023005192A (en) |
| WO (1) | WO2022096604A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR125130A1 (en) * | 2021-03-19 | 2023-06-14 | Heidelberg Pharma Res Gmbh | B LYMPHOCYTE SPECIFIC ANTIBODY AND AMATOXIN CONJUGATES |
| US20240165257A1 (en) | 2022-11-01 | 2024-05-23 | Heidelberg Pharma Research Gmbh | Anti-gucy2c antibody and uses thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| MXPA02001911A (en) | 1999-08-24 | 2003-07-21 | Medarex Inc | Human ctla 4 antibodies and their uses. |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| AU2008266951B2 (en) | 2007-06-18 | 2013-12-12 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor PD-1 |
| DE202007018529U1 (en) | 2007-07-07 | 2008-12-04 | Chamalow S.A. | Implantable Radio Frequency Defibrillator R.F. |
| PT2242773T (en) | 2008-02-11 | 2017-09-15 | Cure Tech Ltd | Monoclonal antibodies for tumor treatment |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| LT3192529T (en) | 2009-04-08 | 2020-06-25 | Faulstich, Heinz, Dr. | Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy |
| SG11201601679TA (en) | 2013-09-06 | 2016-04-28 | Aurigene Discovery Tech Ltd | 1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as immunomodulators |
| EP3268047B9 (en) | 2015-03-09 | 2024-01-10 | Heidelberg Pharma Research GmbH | Amatoxin-antibody conjugates |
| EP3222292A1 (en) | 2016-03-03 | 2017-09-27 | Heidelberg Pharma GmbH | Amanitin conjugates |
| WO2018115466A1 (en) | 2016-12-23 | 2018-06-28 | Heidelberg Pharma Research Gmbh | Amanitin antibody conjugates |
| US11198726B2 (en) | 2017-06-02 | 2021-12-14 | Boerhinger Ingelheim International Gmbh | Anti-cancer combination therapy |
| WO2019197654A1 (en) * | 2018-04-13 | 2019-10-17 | Heidelberg Pharma Research Gmbh | Targeted amatoxin conjugate for the treatment of solid tumors |
| SG11202100607RA (en) | 2018-07-31 | 2021-02-25 | Heidelberg Pharma Res Gmbh | Humanized antibodies against psma |
-
2021
- 2021-11-04 IL IL302034A patent/IL302034A/en unknown
- 2021-11-04 JP JP2023526858A patent/JP2023548522A/en active Pending
- 2021-11-04 MX MX2023005192A patent/MX2023005192A/en unknown
- 2021-11-04 CA CA3195572A patent/CA3195572A1/en active Pending
- 2021-11-04 KR KR1020237018353A patent/KR20230104653A/en unknown
- 2021-11-04 WO PCT/EP2021/080688 patent/WO2022096604A1/en active Application Filing
- 2021-11-04 CN CN202180088954.0A patent/CN116744969A/en active Pending
- 2021-11-04 EP EP21802741.5A patent/EP4240424A1/en active Pending
- 2021-11-04 AU AU2021373298A patent/AU2021373298A1/en active Pending
-
2023
- 2023-05-02 CL CL2023001266A patent/CL2023001266A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL302034A (en) | 2023-06-01 |
| CN116744969A (en) | 2023-09-12 |
| EP4240424A1 (en) | 2023-09-13 |
| AU2021373298A1 (en) | 2023-06-08 |
| JP2023548522A (en) | 2023-11-17 |
| MX2023005192A (en) | 2023-05-15 |
| CA3195572A1 (en) | 2022-05-12 |
| KR20230104653A (en) | 2023-07-10 |
| WO2022096604A1 (en) | 2022-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023001266A1 (en) | Composition comprising a combination of immune checkpoint inhibitor | |
| CL2021000048A1 (en) | Eribulin-Based Drug-Antibody Conjugates and Methods for Their Use (Divisional Application 2456-2018) | |
| BR112012026213A8 (en) | PYROLOBENZODIAZEPINE COMPOUNDS, CONJUGATE THEREOF, PHARMACEUTICAL COMPOSITION COMPRISING THE CONJUGATE AND USE THEREOF FOR THE TREATMENT OF A PROLIFERATIVE DISEASE | |
| WO2020236825A3 (en) | Mcl-1 inhibitor antibody-drug conjugates and methods of use | |
| BR112016024363A2 (en) | antibody-drug conjugate and its use for cancer treatment | |
| MX2020012997A (en) | Splicing modulator antibody-drug conjugates and methods of use. | |
| MX2020012679A (en) | Amino-pyrazinecarboxamide compounds, conjugates, and uses thereof. | |
| BRPI1004899B8 (en) | phosphoinositide 3-kinase inhibitor compound, pharmaceutical composition and use of a compound | |
| BR112015026247A8 (en) | compound in combination with a cytidine analogue, pharmaceutical composition comprising them, use thereof and kit | |
| CO2022003703A2 (en) | therapeutic conjugates | |
| AR083786A1 (en) | ANTIDIABETIC COMPOUNDS | |
| BR112022011032A2 (en) | ANTI-CLAUDIN ANTIBODY-DRUG CONJUGATE AND PHARMACEUTICAL USE THEREOF | |
| CL2021001534A1 (en) | Herboxydiene of antibody-drug conjugates and methods of use. | |
| BR112016024619A2 (en) | IgF-1r-Drug Antibody Conjugate and Its Use for Cancer Treatment | |
| BR112012022243A8 (en) | Use of a thioxanthone-based autophagy inhibitor and an autophagy-inducing compound for cancer therapy, pharmaceutical composition and pharmaceutical kit | |
| EA201690321A1 (en) | APPLICATION OF ANTIBODY IMMUNOCONG CONTRACT TO MUC1 AND MAITANZINOID FOR THE TREATMENT OF SOLID TUMORS | |
| BR112015006363A2 (en) | pharmaceutical combinations comprising dual angiopoietin-2 / dll4 binders and anti-vegf-r agents | |
| BR112021025394A2 (en) | Anthracycline derivatives, drug and target binding molecule conjugates, use of drug and target binding molecule conjugate, method of treating a disease in a patient in need of treatment, and pharmaceutical composition | |
| PE20151603A1 (en) | ANTI-LAMP1 ANTIBODIES AND DRUG ANTIBODY CONJUGATES, AND USES OF THEM | |
| BRPI0518619A2 (en) | Method of treating cancer in a mammal, pharmaceutical combination, use of a pharmaceutical composition or combination and immunogenic composition | |
| CL2021002838A1 (en) | Conjugated anti-bcma antibody, compositions comprising the same, and methods of making and using the same. | |
| CO2023012358A2 (en) | b cell-specific amatoxin-antibody conjugates | |
| BR112023000174A2 (en) | BINDER-DRUG COMPOUND, ANTIBODY-DRUG CONJUGATE, PHARMACEUTICAL COMPOSITION, AND USE OF A COMPOUND | |
| UY38265A (en) | DRUG ANTIBODY CONJUGATES FOR ABLATION OF HEMATOPOIETIC STEM CELLS | |
| CO2021002980A2 (en) | Dendrimer formulations |